Kala Pharmaceuticals ( (KALA) ) has released a notification of late filing.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Kala Pharmaceuticals, operating under the name KALA BIO, Inc., has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending September 30, 2025. The delay is primarily due to financial constraints following a default notice from Oxford Finance LLC, which led to a foreclosure process and the sweeping of the company’s cash resources. This situation hindered the company’s ability to pay employees and external advisors necessary for the timely preparation of the report. However, the company has secured a convertible loan agreement to aid in the preparation and filing of the report, which is expected to be completed within five days following the original due date. Despite these challenges, the company does not anticipate any significant changes in its financial results compared to the previous fiscal year. The notification was signed by Mary Reumuth, the Chief Financial Officer and Corporate Secretary, who emphasized ongoing compliance efforts and the company’s commitment to resolving these financial issues.
The most recent analyst rating on (KALA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Kala Pharmaceuticals stock, see the KALA Stock Forecast page.
Spark’s Take on KALA Stock
According to Spark, TipRanks’ AI Analyst, KALA is a Underperform.
Kala Pharmaceuticals faces significant financial difficulties, marked by declining revenues and heavy reliance on debt, which pose serious risks. The technical analysis reflects a strong downtrend, with the stock being oversold, adding to the negative outlook. Valuation is unattractive due to negative earnings and the lack of a dividend, further weighing down the stock’s appeal.
To see Spark’s full report on KALA stock, click here.
More about Kala Pharmaceuticals
Average Trading Volume: 1,119,970
Technical Sentiment Signal: Sell
Current Market Cap: $5.1M
For an in-depth examination of KALA stock, go to TipRanks’ Overview page.